PRESS RELEASE

from NOVACYT (EPA:ALNOV)

Notice of Half Year 2024 Results and Investor Presentation

image 

 

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

 

Notice of Half Year 2024 Results and Investor Presentation

 

Paris, France, and Eastleigh and Manchester, UK – 12 September 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its unaudited financial results for the six months ended 30 June 2024 on Thursday, 26 September 2024.

Investor webinar

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the HY 2024 results will take place at 11.00am BST on Thursday, 26 September 2024.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. 

Investors can sign up for the webinar via:

 

https://www.investormeetcompany.com/novacyt-sa/register-investor 

 

Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

 

Contacts

 

     Novacyt SA                                                                                                                                      https://novacyt.com/investors

     Lyn Rees, Chief Executive Officer                                                                                                                        Via Walbrook PR

     Steve Gibson, Chief Financial Officer                                        

     SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                              +44 (0)20 3470 0470

     Matthew Johnson / Charlie Bouverat (Corporate Finance)                            

Vadim Alexandre / Rob Rees (Corporate Broking)

    Deutsche Numis (Joint Broker)                                                                                                                   +44 (0)20 7260 1000

     Freddie Barnfield / Duncan Monteith / Michael Palser                                  

     Allegra Finance (French Listing Sponsor)                                                                                                   +33 (1) 42 22 10 10

     Rémi Durgetto / Yannick Petit                                      r.durgetto@allegrafinance.com / y.petit@allegrafinance.com 

     Walbrook PR (Financial PR & IR)                                                     +44 (0)20 7933 8780 or novacyt@walbrookpr.com

     Stephanie Cuthbert / Paul McManus /                                                        +44 (0)7796 794 663 / +44 (0)7980 541 893

     Phillip Marriage / Alice Woodings                                                                 +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

•       Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

•       Precision Medicine: DPYD genotyping assay

•       Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

•       Ranger® Technology: automated DNA sample preparation and target enrichment technology

MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only         Range of services for the research industry:

•       Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

•       Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester),

Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth (“ALNOV”).  

For more information, please refer to the website: www.novacyt.com

See all NOVACYT news